0OCD.LSE Medistim ASA
- Market cap
- NOK 4.49B
- P/E
- 60.4x
- P/B
- -
- ROE
- 41.1%
- Dividend yield
- 2.57%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0OCD.LSE undervalued?
Graham numberThe Graham number of Medistim ASA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medistim ASA fundamental analysis
No fundamental analysis for Medistim ASA yet.
Medistim ASA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medistim ASA
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ult…
Full company profileMedistim ASA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medistim ASA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 263M | 296M | 323M | 357M | 356M | 418M | 486M | 521M | 556M | 700M | 818M |
| Gross Profit | 198M | 223M | 244M | 138M | 146M | 170M | 218M | 225M | 235M | 319M | 408M |
| Operating Income | 56.4M | 65.5M | 74.0M | 89.8M | 88.6M | 107M | 136M | 126M | 125M | 196M | 247M |
| EBITDA | 68.1M | 78.7M | 86.3M | 110M | 108M | 132M | 164M | 159M | 159M | 221M | 274M |
| Net Income | 39.1M | 47.6M | 57.1M | 70.3M | 69.4M | 90.9M | 114M | 104M | 104M | 159M | 187M |
| EPS | 2.15 | 2.62 | 3.13 | 3.86 | 3.80 | 4.98 | 6.24 | 5.67 | 5.67 | 8.71 | 10 |
| Balance Sheet | |||||||||||
| Total Assets | 217M | 251M | 270M | 336M | 346M | 403M | 483M | 506M | 575M | 661M | 638M |
| Total Liabilities | 50.3M | 68.1M | 62.9M | 99.2M | 89.0M | 97.2M | 115M | 108M | 138M | 192M | 183M |
| Shareholders' Equity | 167M | 183M | 207M | 237M | 257M | 306M | 368M | 398M | 437M | 468M | 455M |
| Cash & Short-term Investments | 31.1M | 54.4M | 47.5M | 66.7M | 71.9M | 129M | 153M | 154M | 179M | 212M | 176M |
| Total Debt | 1.88M | 10.5M | 7.50M | 36.4M | 39.1M | 24.2M | 17.1M | 17.6M | 34.4M | 75.0M | 26.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 30.5M | 61.6M | 55.8M | 80.4M | 74.1M | 127M | 113M | 113M | 143M | 187M | 195M |
| Capital Expenditure | 13.5M | 14.5M | 16.4M | 13.7M | 10.6M | 11.5M | 21.1M | 29.7M | 6.07M | 5.49M | 195M |
| Free Cash Flow | 17.0M | 47.1M | 39.4M | 66.7M | 63.5M | 117M | 92.4M | 83.5M | 137M | 182M | - |
| Ratios | |||||||||||
| ROE | 23.5% | 26.0% | 27.6% | 29.7% | 27.0% | 29.7% | 31.0% | 26.1% | 23.8% | 34.0% | 41.1% |
| ROA | 18.0% | 18.9% | 21.2% | 20.9% | 20.1% | 22.5% | 23.6% | 20.5% | 18.1% | 24.1% | 29.3% |
| Net Profit Margin | 14.9% | 16.1% | 17.7% | 19.7% | 19.5% | 21.8% | 23.4% | 19.9% | 18.7% | 22.8% | 22.9% |
| Debt to Equity | 0.01x | 0.06x | 0.04x | 0.15x | 0.15x | 0.08x | 0.05x | 0.04x | 0.08x | 0.16x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medistim ASA dividends
- Dividend yield
- 2.57%
- Forward dividend
- -
- Payout ratio
- 68.8%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 109M | 5.99 | 68.8% |
| 2024 | NOK 82.4M | 4.50 | 79.4% |
| 2023 | NOK 82.2M | 4.49 | 79.2% |
| 2022 | NOK 68.4M | 3.74 | 60.0% |
| 2021 | NOK 54.6M | 2.99 | 60.1% |
| 2020 | NOK 50.1M | 2.74 | 72.1% |
| 2019 | NOK 40.9M | 2.25 | 58.2% |
| 2018 | NOK 36.4M | 2.00 | 63.7% |
| 2017 | NOK 31.8M | 1.75 | 66.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Medistim ASA
- Insiders 30.14%
- Institutions 54.17%
- Public & others 15.69%
- Shares outstanding 18.2M
- Free float 11.3M
Medistim ASA company profile
- Company name
- Medistim ASA
- Ticker
- 0OCD.LSE
- ISIN
- NO0010159684
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 159
- Fiscal year end
- December
- Address
- Oekernveien 94, Oslo, Norway, 0579
- Phone
- 47 23 05 96 60
- Website
- medistim.com
About Medistim ASA
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and ultrasound imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which are designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation; ultrasound imaging probes; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Medistim ASA management
10- Ms. Kari Eian KrogstadCEO & President · born 1964
- Mr. Thomas JakobsenChief Financial Officer · born 1969
- Mr. Helge BorslidVice President of Operations
- Ms. Hæge Johanne Krogh WetterhusVice President of Marketing · born 1964
- Mr. Hakon GrotheChief Innovation Officer
- Mr. Mike KarimChief Commercial Officer
- Mr. Jonas TyssoChief R&D Officer
- Monica WeisethVice President of QA\Reg
- Mr. Ole Arne EiksundSVP of Sales APAC · born 1967
- Mr. Ole Jorgen RobsrudManaging Director of 3rd party distribution